Krishna Institute of Medical Sciences Limited

rs,

nager, Department of Corporate Services Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025 Dear Sir, Sub: Investo

Rs. 45,000

entre” in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Rao never turned away any patient from the hospital for want of money. The brand “Krishna

6.9%

Director Private & Confidential 7 Shareholding Pattern - As on 30th June, 2025 Retail Pre IPO, 6.9% Retail & Others, 9.6% Promoters, 34.1% Share Holder Promoter SBI MF Axis MF HDFC MF

9.6%

fidential 7 Shareholding Pattern - As on 30th June, 2025 Retail Pre IPO, 6.9% Retail & Others, 9.6% Promoters, 34.1% Share Holder Promoter SBI MF Axis MF HDFC MF SBI Insurance Kota

34.1%

eholding Pattern - As on 30th June, 2025 Retail Pre IPO, 6.9% Retail & Others, 9.6% Promoters, 34.1% Share Holder Promoter SBI MF Axis MF HDFC MF SBI Insurance Kotak Fund Nomura

6.0%

7,04,880 NIPPON MF 69,67,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII F

5.2%

80 NIPPON MF 69,67,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII

4.4%

NIPPON MF 69,67,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII DII

3.4%

MF 69,67,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII DII FII

3.1%

69,67,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII DII FII DII

2.9%

,698 No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII DII FII DII 8 F

2.3%

No of Shares Share Holding % Category 13,64,89,330 34.1% 6.0% 5.2% 4.4% 3.4% 3.1% 2.9% 2.3% 2.0% 1.9% 1.7% DII DII DII DII DII FII FII DII FII DII 8 FII, 17

“Tulsa-Pro System A non- invasive procedure that uses real-time MRI guidance to precisely deliver thermal ablation for treating BPH (Benign Prostatic Hyperplasia) and prostate cancer, preserving surrounding healthy tissue.”

“Best Super-Specialty Hospital in Telangana National Quality Excellence Awards 2020 Only Hospital in Telangana to get NABH Accredition for Emergency Department 2021 Ranked No.1 in Hyderabad for Cardiology, Neurosciences, Nephrology & Emergency Times Health Survey Times of India Private & Confidential 11 Consistent Performer over 2 decades (Rupees in Millions) 30,670 7,590 25,143 22,235 CAGR: 26.9% 11,287 16,711 6,200 5,766 CAGR: 29.7% 5,217 2,412 263 2005 No.”

“of Hospitals: 18 2005 2010 2015 2020 2022** 2023 2024 2025 Total Revenue *EBITDA 1) *EBITDA before IND AS and other income 2) **FY22 EBITDA includes share of profit from JV (Sunshine) Private & Confidential 12 Q1 FY26 Updates Private & Confidential 13 Financial & Operational Highlights - 1/2 (Rupees in Cr) FINANCIAL HIGHLIGHTS Q1 FY26 Consolidated • Total revenue of INR 879 Cr, a growth of 26.8% on YoY and 9.6% on QoQ basis.”

“• PAT at INR 85 Cr in Q1 FY26 against INR 95 Cr and INR 106 Cr in Q1 FY25 and Q4 FY25 respectively.”

“• Consolidated Key Financials figures are as follows (Rs in Cr) : Particulars Total Income Less : Other Income Revenue from Operations PBT* Add : Interest Add : Depreciation Less : Gain on fair valuation of Call option Consoldiated - FY26 Q1 Results Q1 FY26 Q4 FY25 Q1 FY25 QoQ YoY 878.7 7.1 871.6 113.7 32.6 53.4 - 801.4 4.5 796.9 134.0 26.7 52.6 10.8 693.0 4.6 688.4 127.1 17.9 39.0 - 9.6% 26.8% 9.4% -15.1% 26.6% -10.5% Reported EBITDA (Incl.”

“Capex 350-400 Cr 180-200 Cr 40-50 Cr Cancer Centre / Mother & Child 90-110 Cr All Specialities All Specialities 300-350 Cr 300-350 Cr Revised Expected Year of Operation Q2 FY26 Q2 FY26 Q2 FY26 Q4 FY26 Q1 FY27 Q4 FY27 Private & Confidential 26 KIMS Hospitals, Thane About Thane: Thane’s central location, adequate public transport and multi-lane roads have undoubtedly made it a viable choice for both, home and office buyers.”

VISION

1

OUR MISSION

1

Operational Parameter

1

VISION

To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients. And to be the best place to work for doctors and employees.

OUR MISSION

Provide affordable quality care to our patients with patient-centric systems and processes. Enable clinical outcome-driven excellence by engaging modern medical technology. Provide a strong impetus for doctors to pursue academics and medical research. S T N ATIE P Most Preferred Healthcare Provider DOCTORS EMPLOYEES INVESTO RS Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes Clinical Outcome Driven Excellence Latest Medical Technology Strong Academics & Research Oriented Enriching Atmosphere Collaborative Culture Growth Driven Career Approach Transparent Governance Strong Operational Performance Consistent Growth Private & Confidential 2 Multi Specialty Care Brain • Neurology • Neurosurgery • Psychiatry • Neuro Rehabilitation Heart • Cardiology • Cardiac Surgery • Vascular Surgery • Heart Transplant • Cardio Rehabilitation Lung • Pulmonology • Interventional Pulmonology • Thoracic surgery • Lung Transplant ENT • Ear • Nose • Throat • Head and Neck Sur

Operational Parameter

ARPOB: 60,000 Key Existing Specialities: Cardiology, Cardiothoraci Surgery, Neurology, Neurosurgery, Nephrology, Urology, Orthopaedics, Medical & Surgical Gastroenterology, Oncology (Medical, Surgical & Radiation), Internal Medicine & Critical Care, Cardiology, Gastroenterology, Emergency Medicine, Pulmonology Proposed Specialities to be added - Transplant services (Kidney, Liver, Heart & Lung) Private & Confidential 27 Profit and Loss Statement (Rupees in Millions) Particulars Consolidated Q1 FY26 Q4 FY25 Q1 FY25 QoQ(%) YoY(%) FY25 FY24 YoY(%) Operating Revenue 8,716 7,969 6,884 9.4% 26.6% 30,351 24,982 Other Income Total Revenue EBITDA 71 8,787 1,997 45 8,014 2,025 46 57.8% 54.3% 319 161 6,930 1,840 9.6% -1.4% 26.8% 30,670 25,143 8.5% 8,148 6,533 21.5% 98.1% 22.0% 24.7% EBITDA (%) on total revenue 22.7% 25.3% 26.6% 26.6% 26.0% PBT* 1,137 1,340 1,271 -15.1% -10.5% 5,581 4,595 21.5% PBT (%) on total revenue 12.9% 16.7% 18.3% 18.2% 18.3% PAT* 850 1,061 952 -19.9% -10.7% 4,148 3,359 23.5%